Skip to main content

Table 1 Vorinostat in single agent trials

From: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

HDACI Disease Dose & schedule Phase No. Pts Outcome Reference
Vorinostat Various cancer 400 mg, oral I 476 Tolerated, safe [21]
Vorinostat CTCL 200 mg Bid PO IIb 74 CR: 16%
PR: 67%
SD: 16%
[20]
Vorinostat GI cancer 300 mg Bid PO 3 days/w q21d II 16 safe, PK results [26]
Vorinostat TCC 200 mg Bid PO II 14 study closed [36]
Vorinostat Breast, colon, lung Cancer 200–400 mg Bid PO ×14q21d II 16 SD: 50% [22]
Vorinostat MM 200–300 mg Bid PO × 5d/wq28d/200–400 mg Bid PO × 14d/wq21d I 13 No response [40]
Vorinostat DLBCL 300 mg Bid PO 3 days/week II 18 CR: 5.5%
SD: 5.5%
[23]
Vorinostat Gynecologic tumor 400 mg/d PO II 27 Insufficient activity (PR: 3%) [37]
Vorinostat MDS, leukemia 100–300 mg Bid/TidPO ×14q21d 1 41 MTD:200 mg Bid [24]
Vorinostat Head neck cancer 400 mg qd PO II 12 No response [41]
Vorinostat mesothelioma NR I 13 PR: 15% [35]
  1. CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose; NR: not reported.